



Medical

www.pall.com/blood

Redefining the Business of Blood

*Improve Plasma Yields and Increase Platelet Availability
By Maximizing the Use of Whole Blood Donations*



Redefining the Business of Blood

What does 'Redefining the Business of Blood' mean?

It's taking a fresh look at your operation to pinpoint the "high-return" areas in which to invest your time and resources to optimize your business. Using this valuable insight, you can decide where product availability can be improved and revenue income can be generated.

Pall Medical is committed to providing its expertise to help you optimize your business potential every step of the way.




Maximize your revenue stream with small changes in your strategic planning.

As you make key decisions in the planning phase to address product demand, you can enhance your business and optimize your donor base, maximizing WB donations. You won't need to make big changes to make major improvements in product mix and supply, efficiency and revenue.

Taking the First Step

Business optimization starts with knowing where your center is headed and understanding the challenges you will face in getting there. When you look at your overall business, what are the issues that concern you most?

- ▶ Is importing product an issue for your center? If so, in what ways?
- ▶ Do you have an opportunity to export product? And could this be an important part of your business?
- ▶ Are there competitors moving into the area? Who are your main competitors? In what ways have they affected your business? Are you competing primarily for more donors or for more customers?
- ▶ Is expanding your center's business and customer base a major concern?
- ▶ Are you concerned about collection issues such as recruitment, staffing, processing, etc.?
- ▶ How frequently do you talk to your customers about issues that concern them? What are your plans to change the product offering to meet their needs?
- ▶ How does the need to leukoreduce product affect your center's planning, such as collections space and staffing, lab space and staffing, inventory, etc.?



Get More from Manual Whole Blood Donations

Over fourteen million units of whole blood are collected each year in the U.S. from a shrinking pool of eligible donors. Whole blood has become a valuable resource which needs to be maximized to its fullest potential. A blood collection facility whose objective is whole blood donation, has the greatest potential to redefine their blood business to achieve their goals and satisfy their customer's needs.

Plasma... a resource in high demand. After a period of market fluctuations in the value of plasma earmarked for further manufacturing, the demand for plasma is on the rise.

Whole blood (WB)-derived platelets... an untapped resource. Based on a 2005 survey, platelet concentrates were prepared from only 30.3% of whole blood donations.¹ Though single-donor platelets made up the difference in platelet transfusion needs, the margin between supply and demand is small.



Maximizing plasma yields and increasing platelet availability through WB donations gives your facility the ability to adequately supply leukoreduced RBCs (red blood cells) and address:

- ▶ Supply issues due to donor restrictions related to TRALI (Transfusion Related Acute Lung Injury).
- ▶ High operational costs driven by market economics and regulatory requirements.

Illustrated below, all WB and RBC filtration systems can help you achieve your plasma needs. Selecting the appropriate system depends on tradeoffs between plasma yields and workflow efficiency. Only an RBC or RBC/PLT (red blood cell/platelet) in-line filtration system coupled with a platelet pooling system truly maximizes product yields from WB donations.

Reviewing Your Options – Leukoreduced RBCs with a...

	Category A Focus on Plasma ONLY Workflow Considerations	Category B Focus on Plasma AND LR WB-derived Platelets Improving Product Yields	Category C Focus on LR WB-derived Platelets ONLY Improving Safety and Availability
OPTION 1	Leukotrap® RC System with RC2D Filter	Leukotrap RC with RC2D Filter with Acrodose™ PLus Systems	Leukotrap RC PL and Acrodose PL Systems
OPTION 2	Leukotrap WB with SAVE System	Leukotrap SC RC with Acrodose PLus Systems and Standard Collection Bag	Leukotrap PL and Acrodose PL Systems with Leukotrap SC RC System
OPTION 3	Leukotrap SC RC System		Leukotrap RC with RC2D Filter with Acrodose PLus Systems
OPTION 4			Leukotrap SC RC with Acrodose PLus Systems and Standard Collection Bag

Category A | Focus on Plasma:

Workflow Considerations

Production Logistics

Every year recruitment goals increase to meet the growing demands for blood donations. To achieve these goals, blood drives are occurring at locations distant from the processing center and for longer periods of time. Blood centers may now be challenged with the need for component production growth and longer drive hours, while focusing on overhead costs.

Option #1: Business Optimization Using the Leukotrap RC System with RC2D Filter

- ▶ Improved plasma yields, by as much as 10% over WB in-line systems.
- ▶ Greater flexibility for component staff scheduling with ample timing for filtration up to 72 hours when stored at 1-6 °C.
- ▶ Superior filtration performance across a broad range of processing conditions with reduced filter plugging.
- ▶ Fast flow rates and filtration times that can increase production throughput.
- ▶ Adaptability to semi-automatic processing.
- ▶ Streamlined inventory management from one system that is capable of both hard spins for plasma or soft spins for platelet/plasma production.

Option #2: Business Optimization Using the Leukotrap WB with SAVE System

- ▶ Improved ergonomics from the patented SAVE System to reduce staff injury and accommodate flexibility in staff scheduling.
- ▶ Adaptability to mobile and laboratory settings.
- ▶ Fast flow rates and filtration times.
- ▶ Improved workflow efficiency over dockable systems by 7-fold.²

Choosing the [Leukotrap WB with SAVE System](#) doesn't mean compromising your plasma production needs. In a study comparing plasma yields with a competitive WB in-line system, the plasma yield was significantly higher after a 24-hour cold hold when using the [Leukotrap WB with SAVE System](#).³

Option #3: Business Optimization Using the Leukotrap SC RC System with BPF4™ Filter

Though RBC dockable systems are inherently more labor intensive than in-line systems, for producing leukoreduced RBCs and plasma, using the right dockable system can streamline and improve the workflow efficiency of dockable processing.

The Leukotrap SC RC System is designed to provide maximum flexibility with:

- ▶ Improved ergonomics from the patented SAVE System to reduce staff injury and accommodate flexibility in staff scheduling.
- ▶ Fast flow rates and filtration times.
- ▶ Bulk packaging to reduce set-up and preparation times.



Leukotrap RC System with RC2D Filter

No longer is there a compromise between increasing component production and maintaining optimal operational efficiency when producing leukoreduced RBCs and plasma.

Category B | Focus on Plasma and Platelets:

Improving Product Yields

Production Logistics

To maximize plasma yield, whole blood is centrifuged under hard spin conditions and the plasma is often expressed until the red cells begin to exit the main collection bag. This results in RBCs that have a high hematocrit which may cause filter plugging and slow flow when filtered.

The production of WB-derived platelets has been steadily decreasing while the patient need for platelets has grown exponentially. Despite the growth of single-donor platelet production, platelet availability is still an issue. Single donor platelets have also eroded profit margins and increased overhead due to their significantly higher disposable and capital equipment costs.

Blood collection facilities can capitalize on the clinical benefits of single-donor platelets with the availability of WB-derived to meet increasing platelet transfusion requirements. Non-leukoreduced WB-derived platelets made with [Leukotrap RC System with RC2D Filter](#) can be pooled and leukoreduced using the [Acrodose P_{Lus} System](#) to make a transfusion-ready, therapeutic dose of platelets that are clinically equivalent to a single-donor platelet, an AcrodoseSM Platelet.



Acrodose P_{Lus} System

Option #1: Business Optimization Using the Leukotrap RC System with RC2D Filter and the Acrodose P_{Lus} System

Whether maximizing plasma yields or increasing platelet availability, you can now collect WB in a single system. While doing so you can produce leukoreduced RBC platelets and non-leukoreduced plasma for planned or emergent product needs.

The Leukotrap RC System with RC2D Filter may be the only WB collection system you need to:

- ▶ Increase your plasma yield and revenue by as much as 10% over WB in-line systems with more flexibility to handle RBCs prepared under extreme spin conditions, or
- ▶ Increase platelet availability by making non-leukoreduced platelets and processing them using the Acrodose P_{Lus} System to make value-added Acrodose Platelets.

Option #2: Business Optimization Using the Leukotrap SC RC System with BPF4™ Filter and the Acrodose P_{Lus} System

Though RBC dockable systems are inherently more labor intensive than in-line systems for producing leukoreduced RBCs, the combination of a standard blood collection set and dockable leukoreduction system may be the best solution to achieve your platelet and plasma needs. WB can be collected in standard trade bags – Nutricel® Additive System or CPDA-1 Blood Collection Sets. The RBCs can be processed using the [Leukotrap SC RC System with BPF4™ Filter](#). When the non-leukoreduced platelets are processed using the [Acrodose P_{Lus} System](#), you have the value-added availability of Acrodose Platelets.

No longer is there the need to compromise when it comes to maximizing plasma yields and increasing platelet availability.

Category C | Focus on Platelets:

Improving Safety and Availability

Production Logistics

Blood collection facilities can capitalize on the clinical benefits of single-donor platelets with the availability of WB-derived platelets to meet increasing platelet transfusion requirements by making AcrodoseSM Platelets. An Acrodose Platelet is a leukoreduced, pooled, ABO-matched and bacteria-tested product made from WB-derived platelets. This innovative product is designed to improve platelet safety and availability, all at a lower cost than single-donor platelets.

An Acrodose Platelet breaks down the barriers of traditional thinking that differentiate whole blood platelets from apheresis platelets by providing the highest levels of safety with no clinical sacrifice in the following critical areas:

- ▶ **Platelet Quality:** In vitro and in vivo studies suggest that pooled, stored, ABO-matched platelets are comparable in quality to single-donor platelets.⁴
- ▶ **Platelet Dosing:** Acrodose Platelets can easily be targeted to consistently meet single-donor platelet counts (at least 3.0×10^{11} platelets in a dose).
- ▶ **Bacteria Detection:** Acrodose Platelets use the same culture-based bacteria detection systems as single-donor platelets making these two products comparable.⁵
- ▶ **Donor Exposure:** Although the concern over donor exposure to viruses during pre-storage pooling is real, the advent of nucleic acid testing (NAT) has significantly reduced this risk.⁵



AcrodoseTM Systems are designed for use with either leukoreduced or non-leukoreduced platelets. There is also an option of having a pre-attached platelet bacteria detection system (Pall eBDS) with these systems.

Option #1: Business Optimization Using the Leukotrap RC PL System with the Acrodose PL System is a winning combination.

All your products are leukoreduced after the WB is processed. When the leukoreduced platelets are processed using the Acrodose PL System, you have the added availability of Acrodose Platelets.

Option #2: Business Optimization Using the Leukotrap PL System with the Acrodose PL System may be the best solution for your platelet and leukoreduced RBC needs if you are not leukoreducing all of our RBCs.

When the leukoreduced platelets are processed using the [Acrodose PL System](#) you have the added availability of [Acrodose Platelets](#).

Option #3: Business Optimization Using the Leukotrap RC System with RC2D Filter and the Acrodose PLus System:

Non-leukoreduced whole blood derived platelets made with [Leukotrap RC System with RC2D Filter](#) can be pooled and leukoreduced using the [Acrodose PLus System](#) to make a transfusion-ready, therapeutic dose of platelets that are clinically equivalent to a single-donor platelet – an Acrodose Platelet.

Option #4: Business Optimization Using the Leukotrap SC RC System with BPF4TM Filter with the Acrodose PLus System:

Though RBC dockable systems are inherently more labor intensive than in-line systems for producing leukoreduced RBCs, a combination of standard blood collection sets and dockable leukoreduction systems may be the best solution to obtain your platelet and plasma needs. WB can be collected in standard trade bags – [Nutricel[®] Additive System](#) or [CPDA-1 Blood Collection Sets](#). The RBC can be processed using the [Leukotrap SC RC System with BPF4 Filter](#). When the non-leukoreduced platelets are processed using the [Acrodose PLus System](#) you have the added availability of [Acrodose Platelets](#).



Acrodose PL System



References

- Whitaker BI, Sullivan M (Ed.). (2005). In the 2005 Nationwide Blood Collection and Utilization Survey Report. Rockville, MD: US Dept. of Health & Human Services last accessed Sept, 2007 at <http://www.aabb.org/apps/docs/05nbcusrpt.pdf>
- Gingras A. A formula to calculate component lab workload based on time studies for the leukoreduction (LR) process. *Transfusion* 1999; 39 (Suppl):A80-P.
- Russell R. A comparison between Leukotrap® WB Filter with the Pall SAVE System and competitive Product A's whole blood filtration characteristics, Part Number 33391, Pall Corporation 2006.
- Anderson NA, Gray S, Copplestone JA, Chan DC, et al. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. *Transfusion Medicine* 1997; 7(1):33-9.
- Ortolano, GA, and Cervia, JS Pool and Store Platelets – Augmenting Quality Platelet Supply To Meet Transfusion Requirements, STRPitQty10.05, Pall Corporation, 2005.



United States

25 Harbor Park Drive
Port Washington, NY 11050


1.800.289.7255 toll free phone (USA)
1.516.484.3600 phone
1.516.484.3651 fax

Visit us on the Web at www.pall.com/redefining

International Offices

Pall Corporation has offices and plants throughout the world in locations such as: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, India, Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States and Venezuela. Distributors in all major industrial areas of the world. To locate the Pall office or distributor nearest you, visit www.pall.com/contact.

The information provided in this literature was reviewed for accuracy at the time of publication. Product data may be subject to change without notice. For current information consult your local Pall distributor or contact Pall directly. This product, and its use, may be covered by one or more patents including EP 0,910,451; US 5,399,268; US 5,580,465; US 5,587,070; US 5,670,060; US 5,679,264; US 5,690,815; US 5,721,024; US 5,968,619; US 6,060,138; US 6,231,770.

© 2011, Pall Corporation. Pall, , Acrodose, BPF4, Leukotrap, and Nutricel are trademarks of Pall Corporation. ® indicates a trademark registered in the USA. **Redefining the Business of Blood**, and Acrodose are service marks of Pall Corporation.

